Suppr超能文献

新型缓激肽B1受体拮抗剂ELN441958的药理、药代动力学及灵长类动物镇痛效果

Pharmacological, pharmacokinetic, and primate analgesic efficacy profile of the novel bradykinin B1 Receptor antagonist ELN441958.

作者信息

Hawkinson Jon E, Szoke Balazs G, Garofalo Albert W, Hom Dennis S, Zhang Hongbing, Dreyer Mark, Fukuda Juri Y, Chen Linda, Samant Bhushan, Simmonds Stellanie, Zeitz Karla P, Wadsworth Angie, Liao Anna, Chavez Raymond A, Zmolek Wes, Ruslim Lany, Bova Michael P, Holcomb Ryan, Butelman Eduardo R, Ko Mei-Chuan, Malmberg Annika B

机构信息

Lead Discovery and Optimization, Elan Pharmaceuticals, South San Francisco, CA 94080, USA.

出版信息

J Pharmacol Exp Ther. 2007 Aug;322(2):619-30. doi: 10.1124/jpet.107.120352. Epub 2007 Apr 30.

Abstract

The bradykinin B(1) receptor plays a critical role in chronic pain and inflammation, although efforts to demonstrate efficacy of receptor antagonists have been hampered by species-dependent potency differences, metabolic instability, and low oral exposure of current agents. The pharmacology, pharmacokinetics, and analgesic efficacy of the novel benzamide B(1) receptor antagonist 7-chloro-2-[3-(9-pyridin-4-yl-3,9-diazaspiro[5.5]undecanecarbonyl)phenyl]-2,3-dihydro-isoindol-1-one (ELN441958) is described. ELN441958 competitively inhibited the binding of the B(1) agonist ligand [(3)H]desArg(10)-kallidin ([(3)H]DAKD) to IMR-90 human fibroblast membranes with high affinity (K(i) = 0.26 +/- 0.02 nM). ELN441958 potently antagonized DAKD (but not bradykinin)-induced calcium mobilization in IMR-90 cells, indicating that it is highly selective for B(1) over B(2) receptors. Antagonism of agonist-induced calcium responses at B(1) receptors from different species indicated that ELN441958 is selective for primate over rodent B(1) receptors with a rank order potency (K(B), nanomolar) of human (0.12 +/- 0.02) approximately rhesus monkey (0.24 +/- 0.01) > rat (1.5 +/- 0.4) > mouse (14 +/- 4). ELN441958 had good permeability and metabolic stability in vitro consistent with high oral exposure and moderate plasma half-lives in rats and rhesus monkeys. Because ELN441958 is up to 120-fold more potent at primate than at rodent B(1) receptors, it was evaluated in a primate pain model. ELN441958 dose-dependently reduced carrageenan-induced thermal hyperalgesia in a rhesus monkey tail-withdrawal model, with an ED(50) approximately 3 mg/kg s.c. Naltrexone had no effect on the antihyperalgesia produced by ELN441958, indicating a lack of involvement of opioid receptors. ELN441958 is a novel small molecule bradykinin B(1) receptor antagonist exhibiting high oral bioavailability and potent systemic efficacy in rhesus monkey inflammatory pain.

摘要

缓激肽B(1)受体在慢性疼痛和炎症中起关键作用,尽管目前用于证明受体拮抗剂疗效的努力因物种依赖性效力差异、代谢不稳定性以及现有药物口服暴露量低而受到阻碍。本文描述了新型苯甲酰胺B(1)受体拮抗剂7-氯-2-[3-(9-吡啶-4-基-3,9-二氮杂螺[5.5]十一烷羰基)苯基]-2,3-二氢异吲哚-1-酮(ELN441958)的药理学、药代动力学和镇痛效果。ELN441958以高亲和力(Ki = 0.26±0.02 nM)竞争性抑制B(1)激动剂配体[(3)H]去精氨酸(10)-缓激肽([(3)H]DAKD)与IMR-90人成纤维细胞膜的结合。ELN441958有效拮抗DAKD(而非缓激肽)诱导的IMR-90细胞内钙动员,表明其对B(1)受体的选择性远高于B(2)受体。对不同物种B(1)受体激动剂诱导的钙反应的拮抗作用表明,ELN441958对灵长类动物B(1)受体的选择性高于啮齿动物,其效价顺序(K(B),纳摩尔)为人类(0.12±0.02)≈恒河猴(0.24±0.01)>大鼠(1.5±0.4)>小鼠(14±4)。ELN441958在体外具有良好的通透性和代谢稳定性,与大鼠和恒河猴体内高口服暴露量和中等血浆半衰期一致。由于ELN441958对灵长类动物B(1)受体的效力比对啮齿动物高120倍,因此在灵长类疼痛模型中对其进行了评估。在恒河猴甩尾模型中,ELN441958剂量依赖性地减轻了角叉菜胶诱导的热痛觉过敏,ED50约为3 mg/kg皮下注射。纳曲酮对ELN441958产生的抗痛觉过敏没有影响,表明阿片受体未参与其中。ELN441958是一种新型小分子缓激肽B(1)受体拮抗剂,在恒河猴炎症性疼痛中表现出高口服生物利用度和强效全身疗效。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验